Sumitomo Dainippon changes its name to Sumitomo Pharma
Sumitomo Dainippon Pharma renamed itself Sumitomo Pharma as of April 1 to push the globally recognized brand of the “Sumitomo” group in a bid to grow further after going through a major transformation including big M&As, the company said.
The name change came 16 and a half years after the merger of Sumitomo Pharmaceuticals and Dainippon Pharmaceutical in October 2005, which created Sumitomo Dainippon Pharma.
Related news and insights
Bone Therapeutics the cell therapy company addressing unmet medical needs in orthopedics and Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in the development of optimized formulations of arsenic salts and their application in inflammatory conditions and other potential new indications, announce the signature of a binding contribution agreement to combine the operations of both companies by means of a share for share exchange, subject to the approval of the shareholders' meeting
Pfizer Inc. and Global Blood Therapeutics, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD)
Gilead Sciences, Inc.and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.